-
Posted by
Two Blokes Jun 10 -
Filed in
Stock
-
7 views
Insmed achieved positive phase 2b results for TPIP in PAH, meeting all endpoints and paving the way for phase 3 trials in 2025-2026. The global pulmonary arterial hypertension market is expected to reach $12.2 billion by 2032. Brensocatib's NDA for bronchiectasis is under Priority Review, with a PDUFA date of August 12, 2025, targeting an untapped market.
